Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tolerx Inc.

www.tolerx.com

Latest From Tolerx Inc.

Looking For The New Lantus: Next-Gen Diabetes Hopefuls Defy Risks

The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.

BioPharmaceutical Clinical Trials

MorphoSys Nabs GSK As Latest Partner For RA Drug

The British pharma is expanding its portfolio in rheumatoid arthritis through a mid-stage tie-up with German biotech MorphoSys. GSK will take over all development of the antibody and could pay milestones up to €425 million.

BioPharmaceutical Strategy

Andromeda's DiaPep277 : beating a path to type 1 diabetes?

Andromeda Biotech has released top-line results for its lead product, DiaPep277, that suggest it could prove an effective immunotherapeutic product for patients with newly diagnosed type 1 diabetes.

Metabolic Disorders South Africa

Autoimmune therapies found wanting in type 1 diabetes

Autoimmune treatments in type 1 diabetes hold forth the promise of preserving the body’s own insulin production. However, three late-stage candidates – teplizumab, otelixizumab, and Diamyd – have failed to show that they can prevent beta-cell destruction in type 1 patients.

Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • TolerRx Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tolerx Inc.
  • Senior Management
  • Douglas J Ringler, Pres. & CEO
    Antonin (Tony) de Fougerolles, PhD, CSO
  • Contact Info
  • Tolerx Inc.
    Phone: (617) 354-8100
    300 Technology Sq.
    3rd Fl.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register